One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes
Significant reductions in glycated haemoglobin and body weight have been shown with oral semaglutide compared with placebo and several anti-diabetic agents [3,4,5,6,7,8,9,10]
Accumulator adjustment programs (AAPs), now standard practice at most large PBMs, allow the PBM to prevent manufacturer copay card payments from counting toward a patients deductible or out-of-pocket maximum
And shell be watching to see how the legal fight influences public trust and the market for such drugs while raising larger questions about what level of drug risk warnings are deemed sufficient
The modified polypeptide can be combined with human albumin to enhance the resistance to DPP-4 and prolong the half-life to 5-6 days